During this segment, Bruce Feinberg, DO, notes that oncologists commonly question the role of palliative care specialists, as oncologists consider pain management to be part of their job and are often concerned that referring patients to yet another type of oncology professional makes managing a patient’s disease more complex.
Ted Okon, MBA, executive director of the Community Oncology Alliance, remarks that not every patient needs to be referred to a palliative care specialist. Rather, he suggests that palliative care should be integrated into oncology practices.
Every healthcare professional within an oncology practice who contributes to a patient’s care needs to better understand what palliative care truly is, suggests Mr Okon. He adds that many people think that palliative care is end-of-life care, but it is not.
He advises that in many instances, the oncology practice can provide palliative care for patients, and that only patients in unique situations need a referral to a palliative care specialist.
Mr Okon says that the emphasis should always be placed on what is appropriate for the patient. “This is about the quality of life for the patient,” he adds.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces at AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More